FDA slaps hold on DBV peanut allergy trial in call for protocol changes

The FDA has grounded DBV Technologies’ latest phase 3 peanut allergy clinical trial before it even had a chance to take flight. Just weeks after DBV trumpeted the finalization of the protocol, the FDA has placed a partial clinical hold on the study and requested changes to the design of the study.